Please assess the completion status of the following clinical trial:

Trial Title: Study of TRAVATAN in Subjects With Iris Pigmentation Changes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion:~* Diagnosis of open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component) or ocular hypertension;~* Has experienced an iris pigmentation change while dosing with TRAVATAN;~* Currently dosing with TRAVATAN;~* Other protocol-defined inclusion criteria may apply.~Exclusion:~* Any form of glaucoma other than open-angle glaucoma (with or without a pigment dispersion or pseudoexfoliation component) or ocular hypertension;~* Not currently using TRAVATAN;~* Females of childbearing potential if pregnant, breast-feeding, or not using highly effective birth control measures;~* History of any severe ocular pathology (including severe dry eye);~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TRAVATAN (Type: None): Travoprost, 0.004% ophthalmic solution, 1 drop to the study eye once daily in the evening for up to 5 years

Based on this trial design, predict the completion outcome and termination type (if applicable).